Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Bioxytran, Inc. (BIXT : OTC)
 
 • Company Description   
BioXyTran Inc. is a biotechnology company. It develops anti-necrosis drugs to treat medical conditions resulting from ischemia. The company's product pipeline consists of BXT-25 and BXT-252 which are in clinical stage. BioXyTran Inc. is based in Newton, United States.

Number of Employees: 3

 
 • Price / Volume Information   
Yesterday's Closing Price: $0.34 Daily Weekly Monthly
20 Day Moving Average: 1,930 shares
Shares Outstanding: 110.84 (millions)
Market Capitalization: $37.13 (millions)
Beta: 0.03
52 Week High: $0.75
52 Week Low: $0.00
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -10.67% 0.62%
12 Week 234.00% 267.21%
Year To Date -16.25% 2.33%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
75 2ND AVE SUITE 605 STE 605
-
NEEDHAM,MA 02464
USA
ph: 617-494-1199
fax: -
None http://www.bioxytraninc.com
 
 • General Corporate Information   
Officers
David Platt - Chief Executive Officer; Chairman and Director
Ola Soderquist - Chief Financial Officer; Treasurer; Secretary
Dale H. Conaway - Director
Alan M. Hoberman - Director
Hana Chen-Walden - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 09075D102
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 05/23/22
Share - Related Items
Shares Outstanding: 110.84
Most Recent Split Date: (:1)
Beta: 0.03
Market Capitalization: $37.13 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 05/23/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: -
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -%
vs. Previous Quarter: 100.00%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
03/31/22 - -
12/31/21 - -
09/30/21 - -
ROA
03/31/22 - -
12/31/21 - -735.08
09/30/21 - -639.43
Current Ratio
03/31/22 - -
12/31/21 - 0.02
09/30/21 - 0.28
Quick Ratio
03/31/22 - -
12/31/21 - 0.02
09/30/21 - 0.28
Operating Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Net Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Pre-Tax Margin
03/31/22 - -
12/31/21 - -
09/30/21 - -
Book Value
03/31/22 - -
12/31/21 - -0.03
09/30/21 - -0.02
Inventory Turnover
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Equity
03/31/22 - -
12/31/21 - -
09/30/21 - -
Debt-to-Capital
03/31/22 - -
12/31/21 - -
09/30/21 - -
 

Powered by Zacks Investment Research ©